tetrabenazine

Tetrabenazine (Ro 1-9569) is a former antipsychotic drug used to treat various movement disorders. It inhibits neurotransmitter uptake into adrenergic storage vesicles and serves as a high-affinity label for the vesicle transport system.

Tetrabenazine methanesulfonate is a medicine formerly utilized as an antipsychotic and therapy for various movement disorders. Tetrabenazine methanesulfonate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affin

(+)-Tetrabenazine ((3R,11bR)-Tetrabenazine) is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Tetrabenazine Racemate (Rubigen) is a selective and reversible inhibitor of vesicular monoamine transporter-2 (VMAT-2). Tetrabenazine Racemate blocks neurotransmitter uptake into adrenergic storage vesicles and has been used as a high-affinity label for the vesicle transport system.

Tetrabenazine Metabolite ((-)-β-HTBZ), a vesicles monoamine transporter 2 (VMAT2) inhibitor, is an active metabolite of Tetrabenazine. Tetrabenazine Metabolite has a high affinity for VMAT2 with a Ki of 13.4 nM. Tetrabenazine Metabolite is often used to study chorea associated with Huntington's disease and other hyperactivity disorders.

Tetrabenazine-D6 is the deuterium-labeled Tetrabenazine. Tetrabenazine (T0719) is a VMAT-inhibitor used for the treatment of hyperkinetic movement disorder.

(3R,11bR)-Tetrabenazine-D6 is a deuterated compound of  (3R,11bR)-Tetrabenazine (T13134). (3R,11bR)-Tetrabenazine has a CAS number of 1026016-83-0. (+)-Tetrabenazine is a reversible vesicular monoamine transporter 2 (VMAT-2) inhibitor, inhibits transport by VMAT2 with 10-fold greater potency than transport by VMAT1.

Trans (2,3)-Dihydrotetrabenazine is a Tetrabenazine metabolite, shows inhibition activity on vesicular monoamine transporter (VMAT2).

(2R,3S,11bS)-9,10-dimethoxy-3-(2-methylpropyl)-1H,2H,3H,4H,6H,7H,11bH-pyrido[2,1-a]isoquinolin-2-ol is an impurity of Tetrabenazine, which is a VMAT inhibitor used in the treatment of hyperkinetic movement disorder.

(2S,3S,11bR)-Dihydrotetrabenazine ((2S,3S,11bR)-DHTBZ) is a highly selective inhibitor of vesicular monoamine transporter 2 (VMAT2) with a Ki value of 593 nM. It suppresses the vesicular transport of monoamine neurotransmitters, such as dopamine and serotonin, leading to reduced release into the synaptic cleft. This compound holds potential for research in Huntington's disease and other hyperkinetic movement disorders.

NBI-98782 ((+)-α-DHTBZ) is an inhibtior of vesicular monoamine transporter (VMAT2) (Ki: 0.97 nM)

JJC8-089, a dopamine transporter (DAT) inhibitor, might enhance motivation-related dysfunctions by increasing effortful behavior in goal-oriented activities. This compound significantly counteracted the low-effort effects induced in rats by the VMAT-2 inhibitor Tetrabenazine, and elevated the selection of high-effort fixed ratio 5 lever presses associated with food intake.